Changes in Body Fat Distribution on Dual-Energy X-Ray Absorptiometry in Black South Africans Starting First-Line Antiretroviral Therapy

AIDS Patient Care and STDs

Volumn 30, Issue 10, 2016, Pages 455-462

  Abrahams, Zulfa ^a   Levitt, Naomi ^a   Lesosky, Maia ^b   Maartens, Gary ^a   Dave, Joel ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b School of Public Health and Family Medicine   (South Africa)

Author keywords

ART; DEXA; lipoatrophy; lipodystrophy; lipohypertrophy

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTHROPOMETRY; ANTIVIRAL THERAPY; ARTICLE; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPERITONEAL FAT; LIPOATROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; SEX DIFFERENCE; SOUTH AFRICAN; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE; WEIGHT GAIN; ADVERSE EFFECTS; BLACK PERSON; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; ETHNOLOGY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; INTRAABDOMINAL FAT; LIPODYSTROPHY; PHOTON ABSORPTIOMETRY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ABSORPTIOMETRY, PHOTON; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY FAT DISTRIBUTION; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INTRA-ABDOMINAL FAT; LIPODYSTROPHY; MALE; RISK FACTORS;

EID: 84992110600     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0183     Document Type: Article

References (29)

1. Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl JMed 1998; 338:853-860.
2. De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: Lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013;8:e63623.
3. Van Griensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudinecontaining first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007;101:793-798.
4. Abrahams Z, Dave JA, Maartens G, Lesosky M, Levitt NS. The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings. AIDS Res Ther 2014;66:839-844.
5. Bussmann H, Wester CW, Thomas A, et al. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: Two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009;51:37-46.
6. Mutimura E, Stewart A, Rheeder P, Crowther NJ. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:451-455.
7. Carter V, Hoy J, Bailey M, Colman P, Nyulasi I, Mijch A. The prevalence of lipodystrophy in an ambulant HIV-infected population: It all depends on the definition. HIV Med 2001; 2:174-180.
8. Casado JL, Iglesias V, del Palacio M, et al. Social isolation in HIV-infected patients according to subjective patient assessment and DEXA-confirmed severity of lipodystrophy. AIDS Care 2013;25:1-5.
9. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavirlamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-196.
10. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109.
11. George JA, Venter WD, Van Deventer HE, Crowther NJ. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses 2009; 25:771-781.
12. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55: 39-48.
13. Department of Health. The South African Antiretroviral Treatment Guidelines. 2013 [Cited 2016 January 8].Available at: www.sahivsoc.org/upload/documents/2013%20ART% 20Guidelines-Short%20Combined%20FINAL%20draft%20 guidelines%2014%20March%202013.pdf (Last accessed January 8, 2016).
14. Goedecke JH, Micklesfield LK, Levitt NS, et al. Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. AIDS Res Hum Retroviruses 2013;29:557-563.
15. Micklesfield LK, Goedecke JH, Punyanitya M, Wilson KE, Kelly TL. Dual-energy x-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity 2012;20:1109-1114.
16. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-1818.
17. Kolta S, Flandre P, Ngo Van P, et al. Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ ritonavir. Results of theMONARK trial. Curr HIV Res 2011; 9:31-39.
18. Valantin M, Flandre P, Kolta S, Duvivier C, Algarte Genin M. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with darunavir/ritonavir (DRV/ r) monotherapy versus 2 NRTIs DRV/r in the MONOIANRS 136 Randomized Trial: Results at 48 weeks. 17th Conference on retroviruses and opportunistic infections. February 16-19, 2010, San Francisco, USA, Poster O-262.
19. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: Prevalence, severity and correlates of risk in Australia. HIV Med 2003;4:293-301.
20. Iwuala SO, Lesi OA, Fasanmade OA, Sabir AA, Olamoyegun MA, Okany CC. Prevalence of and risk factors for lipoatrophy in patients with HIV infection in Nigeria. AIDS Res Treat 2015;2015:402638.
21. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations: Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003;34:58-61.
22. Shisana O, Labadarios D, Rehle T, et al. South African National Health and Nutrition Examination Survey (SANHANES-1). Cape Town, South Africa: HSRC Press; 2014.
23. McComsey G, Rightmire A, Wirtz V, Yang R, Mathew M, McGrath D. Changes in body composition with ritonavirboosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: A 96-week randomized, controlled study. Clin Infect Dis 2009;48:1323-1326.
24. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-979.
25. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc 2004;292:191-201.
26. Hurley E, Coutsoudis A, Giddy J, Knight S, Loots E, Esterhuizen T. Weight evolution and perceptions of adults living with HIV following initiation of antiretroviral therapy in a South African urban setting. S Afr Med J 2011; 101:645-650.
27. Devanathan R, Esterhuizen TM, Govender RD. Overweight and obesity amongst black women in Durban, KwaZulu-Natal: A 'disease' of perception in an area of high HIV prevalence. Afr J Pri Health Care Fam Med 2013;5:450.
28. Matoti-Mvalo T, Puoane T. Perceptions of body size and its associationwithHIV/AIDS. SAfr JClin Nut 2011;24:40-45.
29. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011;25: 1405-1414.